EBS
Emergent BioSolutions Inc
$
10.040
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
10.170
Open
9.050
VWAP
9.80
Vol
1.13M
Mkt Cap
527.30M
Low
9.020
Amount
11.06M
EV/EBITDA(TTM)
4.54
Total Shares
52.40M
EV
944.90M
EV/OCF(TTM)
72.68
P/S(TTM)
0.71
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
295.00M
+109.37%
1.100
-600%
275.00M
+23.76%
0.980
-17.65%
217.50M
+11.71%
0.236
-140.77%
Estimates Revision
The market is revising Upward the revenue expectations for Emergent BioSolutions Inc. (EBS) for FY2025, with the revenue forecasts being adjusted by 1.07% over the past three months. During the same period, the stock price has changed by 8.78%.
Revenue Estimates for FY2025
Revise Upward
+1.07%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+39.64%
In Past 3 Month
Stock Price
Go Up
+8.78%
In Past 3 Month
1 Analyst Rating
Wall Street analysts forecast EBS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EBS is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.040
Low
15.00
Averages
15.00
High
15.00
Current: 10.040
Low
15.00
Averages
15.00
High
15.00
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$15
2025-04-01
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$15
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$15
2025-03-21
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$15
2025-03-21
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$15
2025-03-04
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$15
2025-03-04
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$15
2025-01-21
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$15
2025-01-21
Reiterates
Strong Buy
Reason
Hikma Pharmaceuticals (HKMPF) announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (EBS) for the sale of Kloxxado naloxone HCl nasal spray 8 mg in the U.S. and Canada. Kloxxado was approved by the U.S. FDA in April 2021 for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. Emergent distributes Narcan Nasal Spray 4 mg, which is the first FDA-approved over-the-counter naloxone product for the emergency treatment of opioid overdose.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$15
2025-01-10
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$15
2025-01-10
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Initiates
$15
2024-12-30
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$15
2024-12-30
Initiates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Emergent BioSolutions Inc (EBS.N) is 3.38, compared to its 5-year average forward P/E of 14.09. For a more detailed relative valuation and DCF analysis to assess Emergent BioSolutions Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
14.09
Current PE
3.38
Overvalued PE
50.85
Undervalued PE
-22.66
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-668.93
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2387.55
Undervalued EV/EBITDA
-3725.41
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.94
Current PS
0.00
Overvalued PS
1.78
Undervalued PS
0.10
Financials
Annual
Quarterly
FY2025Q3
YoY :
-21.34%
231.10M
Total Revenue
FY2025Q3
YoY :
-7.20%
65.70M
Operating Profit
FY2025Q3
YoY :
-55.40%
51.20M
Net Income after Tax
FY2025Q3
YoY :
-55.83%
0.91
EPS - Diluted
FY2025Q3
YoY :
-103.85%
-5.70M
Free Cash Flow
FY2025Q3
YoY :
+7.67%
62.74
Gross Profit Margin - %
FY2025Q3
YoY :
-98.53%
0.18
FCF Margin - %
FY2025Q3
YoY :
-43.31%
22.15
Net Margin - %
FY2025Q3
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
391.6K
USD
2
3-6
Months
130.7K
USD
2
6-9
Months
310.8K
USD
3
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
349.8K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
61.6K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
16.0K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
391.6K
USD
2
3-6
Months
130.7K
USD
2
6-9
Months
310.8K
USD
3
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
349.8K
USD
Months
0-12
0
0.0
USD
Months
EBS News & Events
Events Timeline
2025-10-29 (ET)
2025-10-29
16:40:26
Emergent BioSolutions projects FY25 revenue between $775M and $835M, with consensus at $799.1M.
2025-10-29
16:38:24
Emergent BioSolutions Announces Q3 EPS of $1.06, Down from $1.37 Last Year
2025-10-20 (ET)
2025-10-20
10:36:33
Authorities verify community transmission of new Mpox variant in Southern California, according to NBC.
Sign Up For More Events
Sign Up For More Events
News
6.5
11-20Barron's12 Stocks Poised for Europe's Comeback
3.0
11-07NASDAQ.COMSearching for a Bargain on a High-Energy Momentum Stock? Check Out Emergent Biosolutions (EBS)
4.5
11-03NASDAQ.COMMonday's Underperformers: Auto Dealerships and Biotechnology Shares
Sign Up For More News
People Also Watch
SRDX
Surmodics Inc
0
USD
+0.35%
VZLA
Vizsla Silver Corp
4.030
USD
+1.00%
GPRK
GeoPark Ltd
7.700
USD
-1.16%
PACK
Ranpak Holdings Corp
4.520
USD
+5.36%
GOTU
Gaotu Techedu Inc
2.540
USD
+4.96%
OUST
Ouster Inc
19.930
USD
+1.06%
GMRE
Global Medical REIT Inc
32.110
USD
+3.48%
HIFS
Hingham Institution For Savings
272.990
USD
+4.99%
GEVO
Gevo Inc
1.940
USD
+3.74%
SMBK
SmartFinancial Inc
35.670
USD
+2.94%
FAQ
What is Emergent BioSolutions Inc (EBS) stock price today?
The current price of EBS is 10.04 USD — it has increased 10.57 % in the last trading day.
What is Emergent BioSolutions Inc (EBS)'s business?
What is the price predicton of EBS Stock?
What is Emergent BioSolutions Inc (EBS)'s revenue for the last quarter?
What is Emergent BioSolutions Inc (EBS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Emergent BioSolutions Inc (EBS)'s fundamentals?
How many employees does Emergent BioSolutions Inc (EBS). have?